The drug selection process in our International Linked Clinical Trials (iLCT) programme is governed and evaluated by a committee of world leading scientists, physicians and advocates, all experts in their field of Parkinson’s research.

The iLCT Committee

Learn More

Chair iLCT committee
Professor David K. Simon

Learn More

Co-chair iLCT committee
Professor Camille Carroll

Learn More

Professor Roger Barker

Learn More

Patrik Brundin, M.D., Ph.D.

Learn More

Mark R. Cookson, M.D.,Ph.D.

Learn More

Professor David T. Dexter

Learn More

Professor David Devos

Learn More

Ted Dawson, M.D., Ph.D.

Learn More

Howard Federoff, M.D., Ph.D.

Learn More

Brian Fiske, Ph.D.

Learn More

Professor Tom Foltynie

Learn More

Susan Fox, PhD, MB BCh

Learn More

Tim Greenamyre, M.D., Ph.D.

Learn More

Karl Kieburtz, M.D., MPH

Learn More

Jeffrey H. Kordower Ph.D

Learn More

Dimitri Krainc, M.D.

Learn More

Darren Moore Ph.D.

Learn More

Michael Schwarzschild, M.D., Ph.D.

Learn More

David Sulzer, M.D.

Learn More

Professor Per Svenningsson

Learn More

Caroline Tanner, M.D., Ph.D., F.A.A.N.

Learn More

Director of Clinical Development
Dr Richard Wyse MBE

Learn More

Director of Research
Dr Simon Stott